Edition:
India

Anavex Receives Approval To Initiate Phase 2b/3 Clinical Trial Of Anavex®2-73


Tuesday, 3 Jul 2018 

July 3 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES RECEIVES APPROVAL TO INITIATE PHASE 2B/3 CLINICAL TRIAL OF ANAVEX®2-73 FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASE.ANAVEX LIFE SCIENCES RECEIVES APPROVAL TO INITIATE PHASE 2B/3 CLINICAL TRIAL OF ANAVEX®2-73 FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASE.ANAVEX LIFE - RECEIVED APPROVAL BY AUSTRALIAN HUMAN RESEARCH ETHICS COMMITTEE TO INITIATE PHASE 2B/3 48-WEEK SAFETY AND EFFICACY TRIAL OF ANAVEX®2-73. 

Company Quote

3.53
0.22 +6.65%
20 Sep 2019